Log In
Print this Print this


  Manage Alerts
Collapse Summary General Information
Company Cyclacel Pharmaceuticals Inc.
DescriptionOral available small molecule inhibitor of polo-like kinase (PLK1)
Molecular Target Polo-like kinase 1 (PLK1) (STPK13)
Mechanism of ActionPolo-like kinase 1 (PLK1) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentDiscovery
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today